Cytomegalovirus infections after treatment with daclizumab, an anti IL-2 receptor antibody, for prevention of renal allograft rejection

Paul Hengster, Mark D. Pescovitz, Debra Hyatt, Raimund Margreiter, Lars Bäckman, Francois Berthoux, Andrew Bradley, Ginny Bumgardner, James Burdick, Vincenzo Cambi, Gary Chan, Bernard Charpentier, Pierre Daloze, Henrik Ekberg, Göran Gannedahl, Robert Gaston, Phillip Halloran, Ian Hardie, Ingeborg Hauser, Robert JohnsonPaul Keown, Michèle Kessler, Bryce Kiberd, Robert Kirkman, Andrew Lazarovits, Arthur J. Matas, Ferdinand Mühlbacher, Bjorn Nashan, John Neylan, Nils Persson, Mark Pescovitz, Guiseppe Piccoli, Rudolf Pichlmayr, Claudio Ponticelli, Stuart Rodgers, Michael E. Shapiro, David Tiller, Gunnar Tufveson, Gunnar Tyden, Yves Vanrentergehm, Antonio Vercellone, Paul Vialtel, Flavio Vincenti, Samuel Weinstein, Alan Wilkinson

Research output: Contribution to journalArticlepeer-review

50 Scopus citations


Daclizumab is a newly developed humanized anti-IL-2 receptor monoclonal antibody. We describe the effect of adding daclizumab to conventional dual or triple cyclosporine A immunosuppressive therapy on the incidence and nature of cytomegalovirus (CMV) infections in patients receiving a first cadaveric renal graft. In the triple therapy study there was no evidence of any difference in CMV rate or course of disease between the two treatment arms, although in the dual therapy study a decrease in the incidence of CMV infection was observed in the patients treated with daclizumab. The onset of CMV disease was markedly delayed in the daclizumab groups in both studies. Daclizumab can effectively reduce the risk of acute rejection without causing a concomitant increase in opportunistic infections, and by decreasing the need for antirejection therapy may also have a beneficial effect on CMV infection rates.

Original languageEnglish (US)
Pages (from-to)310-313
Number of pages4
Issue number2
StatePublished - Jul 27 1999


Dive into the research topics of 'Cytomegalovirus infections after treatment with daclizumab, an anti IL-2 receptor antibody, for prevention of renal allograft rejection'. Together they form a unique fingerprint.

Cite this